What is your current role on AMYPAD?
I’m Work package 2 co-leader with Juan Domingo Gispert of the Barcelonaβeta Brain Research Center. My role includes quantifying the amyloid load in the AMYPAD Diagnostic and Patient Management Study (DPMS) and contributing to the interpretation of the results. Brain amyloid quantification is an emerging science and it’s stimulating to measure, observe and interpret results with my AMYPAD colleagues.
What is your overall vision?
That one day, through screening, those considered at risk for developing dementia would have the appropriate brain imaging diagnostics and from this they would receive a care pathway that would maintain their cognitive health – in other words preserve who they are.
What do you find most challenging about the project?
The research throws up many questions and avenues for exploration, the challenge is to focus on the insights which will lead the best understanding of Alzheimer’s pathology and its effect on disease progression in the individual.